Premium
The combination of oseltamivir with azithromycin does not show additional benefits over oseltamivir monotherapy in mice infected with influenza A(H1N1)pdm2009 virus
Author(s) -
Fage Clément,
Pizzorno Andrés,
Rhéaume Chantal,
Abed Yacine,
Boivin Guy
Publication year - 2017
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.24911
Subject(s) - oseltamivir , virology , azithromycin , virus , neuraminidase inhibitor , medicine , influenza a virus , covid-19 , biology , microbiology and biotechnology , antibiotics , infectious disease (medical specialty) , disease
The combination of azithromycin, an immunomodulator, with oseltamivir was compared to oseltamivir monotherapy in a lethal BALB/c model of influenza A(H1N1)pdm09 infection. Groups of 14‐16 mice received oral oseltamivir (10 mg/kg once daily for 5 days, starting at day 2 post‐inoculation) alone or combined to azithromycin (a single 100 mg/kg dose, injected intraperitoneally at day 3 post‐inoculation). Based on survival rates, lung viral titers, and pro‐inflammatory cytokine levels, the combination therapy did not provide obvious additional clinical/virological benefits over oseltamivir monotherapy. Additional studies are still needed to better define the potential role of adjunctive immunomodulatory therapy for severe influenza infections.